SubHero Banner

Symbicort® (budesonide/formoterol) – Updated indication

September 11, 2017 – The FDA approved AstraZeneca’s Symbicort (budesonide/formoterol) for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. Symbicort 160/4.5 is also indicated to reduce exacerbations of COPD. Symbicort 160/4.5 is the only strength indicated for the treatment of COPD.

Download PDF